SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Neurogene Inc. (NGNE) News

Follow Neurogene Inc. (NGNE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol NGNE Asset equity Sector Markets 90 days 5 Last 22.165 Updated Nov 09, 2026, 01:23 PM UTC Open live news feed Open NGNE chart & news
M Neurogene Reports $29.0 Million Third-Quarter Net Loss Neurogene reported a $29.0 million net loss for the third quarter of 2026, versus $21.0 million a year earlier. Cash, cash equivalents and short-term investments totaled $359.7 million at quarter-end; the headline says c EQUITY | Nov 09, 2026, 01:23 PM UTC M Neurogene Reports Third-Quarter 2026 Financial Results and Recent Updates Neurogene announced its third-quarter 2026 financial results and highlighted recent corporate updates. EQUITY | Nov 09, 2026, 12:30 PM UTC L Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of EQUITY | Nov 05, 2026, 09:01 PM UTC L Neurogene to participate in H.C. Wainwright 28th conference Neurogene management will participate in the H.C. Wainwright 28th Annual Global Investment Conference, the company said. EQUITY | Sep 08, 2026, 11:30 AM UTC L Neurogene board panel approves Nasdaq Rule 5635 inducement stock option grants Neurogene said its Compensation Committee approved non-qualified stock option inducement grants under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 04, 2026, 08:01 PM UTC L Neurogene shares are trading lower after the company announced a proposed public offering. Neurogene shares are trading lower after the company announced a proposed public offering. EQUITY | Jun 30, 2026, 08:04 PM UTC L Neurogene Reveals Proposed Public Offering; No Size Disclosed Neurogene Inc. (NASDAQ: NGNE ), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public of EQUITY | Jun 30, 2026, 08:02 PM UTC